Logo image of DCGO

DOCGO INC (DCGO) Stock Fundamental Analysis

USA - NASDAQ:DCGO - US2560861096 - Common Stock

1.26 USD
-0.01 (-0.79%)
Last: 10/8/2025, 8:00:01 PM
1.27 USD
+0.01 (+0.79%)
After Hours: 10/8/2025, 8:00:01 PM
Fundamental Rating

3

DCGO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. No worries on liquidiy or solvency for DCGO as it has an excellent financial health rating, but there are worries on the profitability. DCGO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

DCGO had negative earnings in the past year.
DCGO had a positive operating cash flow in the past year.
Of the past 5 years DCGO 4 years were profitable.
The reported operating cash flow has been mixed in the past 5 years: DCGO reported negative operating cash flow in multiple years.
DCGO Yearly Net Income VS EBIT VS OCF VS FCFDCGO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 0 50M -50M

1.2 Ratios

The Return On Assets of DCGO (-4.49%) is worse than 67.33% of its industry peers.
DCGO's Return On Equity of -6.16% is in line compared to the rest of the industry. DCGO outperforms 43.56% of its industry peers.
Industry RankSector Rank
ROA -4.49%
ROE -6.16%
ROIC N/A
ROA(3y)4.86%
ROA(5y)1.57%
ROE(3y)7.06%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
DCGO Yearly ROA, ROE, ROICDCGO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

DCGO's Profit Margin has declined in the last couple of years.
DCGO's Operating Margin has declined in the last couple of years.
The Gross Margin of DCGO (33.65%) is better than 63.37% of its industry peers.
DCGO's Gross Margin has been stable in the last couple of years.
DCGO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 33.65%
OM growth 3Y-8.41%
OM growth 5YN/A
PM growth 3Y-24.17%
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5YN/A
DCGO Yearly Profit, Operating, Gross MarginsDCGO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 10 -10 20 30

7

2. Health

2.1 Basic Checks

DCGO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for DCGO has been reduced compared to 1 year ago.
The debt/assets ratio for DCGO is higher compared to a year ago.
DCGO Yearly Shares OutstandingDCGO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
DCGO Yearly Total Debt VS Total AssetsDCGO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 1.83 indicates that DCGO is not a great score, but indicates only limited risk for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 1.83, DCGO is in line with its industry, outperforming 42.57% of the companies in the same industry.
DCGO has a debt to FCF ratio of 0.58. This is a very positive value and a sign of high solvency as it would only need 0.58 years to pay back of all of its debts.
DCGO's Debt to FCF ratio of 0.58 is amongst the best of the industry. DCGO outperforms 91.09% of its industry peers.
A Debt/Equity ratio of 0.14 indicates that DCGO is not too dependend on debt financing.
DCGO has a Debt to Equity ratio of 0.14. This is in the better half of the industry: DCGO outperforms 72.28% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 0.58
Altman-Z 1.83
ROIC/WACCN/A
WACC8.8%
DCGO Yearly LT Debt VS Equity VS FCFDCGO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 2.36 indicates that DCGO has no problem at all paying its short term obligations.
DCGO has a Current ratio of 2.36. This is in the better half of the industry: DCGO outperforms 79.21% of its industry peers.
A Quick Ratio of 2.36 indicates that DCGO has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 2.36, DCGO belongs to the best of the industry, outperforming 80.20% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.36
Quick Ratio 2.36
DCGO Yearly Current Assets VS Current LiabilitesDCGO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 100M 200M 300M

2

3. Growth

3.1 Past

DCGO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -137.93%.
DCGO shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -9.93% yearly.
DCGO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -41.31%.
DCGO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 24.60% yearly.
EPS 1Y (TTM)-137.93%
EPS 3Y-9.93%
EPS 5YN/A
EPS Q2Q%-257.14%
Revenue 1Y (TTM)-41.31%
Revenue growth 3Y24.6%
Revenue growth 5YN/A
Sales Q2Q%-51.25%

3.2 Future

The Earnings Per Share is expected to decrease by -39.69% on average over the next years. This is quite bad
Based on estimates for the next years, DCGO will show a very negative growth in Revenue. The Revenue will decrease by -17.73% on average per year.
EPS Next Y-274.18%
EPS Next 2Y-63.99%
EPS Next 3Y-39.69%
EPS Next 5YN/A
Revenue Next Year-49.13%
Revenue Next 2Y-28.84%
Revenue Next 3Y-17.73%
Revenue Next 5YN/A

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
DCGO Yearly Revenue VS EstimatesDCGO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 200M 400M 600M
DCGO Yearly EPS VS EstimatesDCGO Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 0 0.2 -0.2 -0.4

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for DCGO. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for DCGO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
DCGO Price Earnings VS Forward Price EarningsDCGO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of DCGO indicates a rather cheap valuation: DCGO is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 1.52
EV/EBITDA N/A
DCGO Per share dataDCGO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

DCGO's earnings are expected to decrease with -39.69% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-63.99%
EPS Next 3Y-39.69%

0

5. Dividend

5.1 Amount

No dividends for DCGO!.
Industry RankSector Rank
Dividend Yield N/A

DOCGO INC

NASDAQ:DCGO (10/8/2025, 8:00:01 PM)

After market: 1.27 +0.01 (+0.79%)

1.26

-0.01 (-0.79%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)08-07 2025-08-07/amc
Earnings (Next)11-05 2025-11-05/amc
Inst Owners52.39%
Inst Owner Change0%
Ins Owners7.1%
Ins Owner Change0.95%
Market Cap123.24M
Analysts78.46
Price Target3.14 (149.21%)
Short Float %4.92%
Short Ratio10.65
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-163.06%
Min EPS beat(2)-311.74%
Max EPS beat(2)-14.37%
EPS beat(4)1
Avg EPS beat(4)-86.11%
Min EPS beat(4)-311.74%
Max EPS beat(4)0.93%
EPS beat(8)2
Avg EPS beat(8)-48.05%
EPS beat(12)3
Avg EPS beat(12)-63.61%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-4.02%
Min Revenue beat(2)-9.68%
Max Revenue beat(2)1.64%
Revenue beat(4)1
Avg Revenue beat(4)-4.48%
Min Revenue beat(4)-9.68%
Max Revenue beat(4)1.64%
Revenue beat(8)4
Avg Revenue beat(8)0.77%
Revenue beat(12)7
Avg Revenue beat(12)1.29%
Revenue beat(16)10
Avg Revenue beat(16)9.13%
PT rev (1m)0%
PT rev (3m)0.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-87.93%
EPS NY rev (1m)-9.18%
EPS NY rev (3m)-30.59%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)2.35%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.12%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.28
P/FCF 1.52
P/OCF 1.41
P/B 0.41
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-0.11
EYN/A
EPS(NY)-0.18
Fwd EYN/A
FCF(TTM)0.83
FCFY65.98%
OCF(TTM)0.89
OCFY70.74%
SpS4.46
BVpS3.04
TBVpS2.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -4.49%
ROE -6.16%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 33.65%
FCFM 18.65%
ROA(3y)4.86%
ROA(5y)1.57%
ROE(3y)7.06%
ROE(5y)1.16%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)8.11%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-8.41%
OM growth 5YN/A
PM growth 3Y-24.17%
PM growth 5YN/A
GM growth 3Y0.21%
GM growth 5YN/A
F-Score5
Asset Turnover1.07
Health
Industry RankSector Rank
Debt/Equity 0.14
Debt/FCF 0.58
Debt/EBITDA N/A
Cap/Depr 38.46%
Cap/Sales 1.34%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.36
Quick Ratio 2.36
Altman-Z 1.83
F-Score5
WACC8.8%
ROIC/WACCN/A
Cap/Depr(3y)50.15%
Cap/Depr(5y)71.98%
Cap/Sales(3y)1.27%
Cap/Sales(5y)2.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-137.93%
EPS 3Y-9.93%
EPS 5YN/A
EPS Q2Q%-257.14%
EPS Next Y-274.18%
EPS Next 2Y-63.99%
EPS Next 3Y-39.69%
EPS Next 5YN/A
Revenue 1Y (TTM)-41.31%
Revenue growth 3Y24.6%
Revenue growth 5YN/A
Sales Q2Q%-51.25%
Revenue Next Year-49.13%
Revenue Next 2Y-28.84%
Revenue Next 3Y-17.73%
Revenue Next 5YN/A
EBIT growth 1Y-153.15%
EBIT growth 3Y14.13%
EBIT growth 5YN/A
EBIT Next Year-159.15%
EBIT Next 3Y-57.49%
EBIT Next 5YN/A
FCF growth 1Y457.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y734.5%
OCF growth 3YN/A
OCF growth 5YN/A